Slentrol

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
24-02-2015
Summary of Product characteristics Summary of Product characteristics (SPC)
24-02-2015
Public Assessment Report Public Assessment Report (PAR)
24-02-2015

Active ingredient:

дирлотапид

Available from:

Zoetis Belgium SA

ATC code:

QA08AB91

INN (International Name):

dirlotapide

Therapeutic group:

Кучета

Therapeutic area:

Препарати против затлъстяване, с изключение на тези, диетични продукти

Therapeutic indications:

Като помощ при лечението на наднорменото тегло и затлъстяването при възрастни кучета. Да се ​​използва като част от цялостната програма за управление на теглото, която включва и подходящи хранителни промени и упражнения.

Product summary:

Revision: 7

Authorization status:

Отменено

Authorization date:

2007-04-13

Patient Information leaflet

                                15
B. ЛИСТОВКА
Лекарствен продукт, който вече не
е разрешен за употреба
16
ЛИСТОВКА ЗА:
SLENTROL 5 MG/ML ПЕРОРАЛЕН РАЗТВОР ЗА КУЧЕТА
1.
ИМЕ И ПОСТОЯНEН АДРЕС НА ПРИТЕЖАТЕЛЯ
НА ЛИЦЕНЗА ЗА УПОТРЕБА
И НА ПРОИЗВОДИТЕЛЯ, АКО ТЕ СА РАЗЛИЧНИ
Притежател на лиценза за употреба:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
Белгия
Производител, отговорен за
освобождаване на партидата:
Pfizer Service Company
Hoge Wei 10
1930 Zaventem
Белгия
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
Белгия
2.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Slentrol 5 mg/ml перорален разтвор за кучета
Dirlotapide
3.
СЪДЪРЖАНИЕ НА АКТИВНАТА(ИТЕ)
СУБСТАНЦЯ(ИИ) И ЕКСЦИПИЕНТА
(ИТЕ)
Dirlotapide 5 mg/ml във вид на безцветен до
бледожълт разтвор.
4.
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
В помощ при контрол и лечение на
наднормено тегло и затлъстяване при
кучета. Вашият
ветеринарен лекар ще определи
необходимото целево тегло и как Slentrol
трябва да се прилага
като част от цялостна програма за
контрол на теглото, която включва
подходяща диета и
упражнения.
5.
ПРОТИВОПОКАЗАНИЯ
Да не се използва при подрастващи
кучета.
Да не се използва по време на
бременност или лактация.
Да не се използва при кучета с
нарушена чернодробна функция.
Да не се изп
                                
                                Read the complete document

Summary of Product characteristics

                                1
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
ПРИЛОЖЕНИЕ I
_ _
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт, който вече не
е разрешен за употреба
2
1.
НАИМЕНОВАНИЕ НА
ВЕТЕРИНАРНОМЕДИЦИНСКИЯ ПРОДУКТ
Slentrol_ _5 mg/ml перорален разтвор за кучета
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Един мл съдържа:
АКТИВНА СУБСТАНЦИЯ:
Dirlotapide
5mg/ml
За пълния списък на ексципиентите, виж
т. 6.1.
3.
ФАРМАЦЕВТИЧНА ФОРМА
Перорален разтвор
Безцветен до светложълт разтвор
4.
КЛИНИЧНИ ДАННИ
4.1
ВИДОВЕ ЖИВОТНИ, ЗА КОИТО Е
ПРЕДНАЗНАЧЕН ВМП
Кучета
4.2
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ, ОПРЕДЕЛЕНИ ЗА
ОТДЕЛНИТЕ ВИДОВЕ ЖИВОТНИ
В помощ при лечение на наднормено
тегло и затлъстяване при възрастни
кучета. SLENTROL
трябва да се прилага като част от
цялостна програма за контрол на
теглото, която включва
подходяща диета и упражнения.
4.3
ПРОТИВОПОКАЗАНИЯ
Да не се използва при подрастващи
кучета.
Да не се използва по време на
бременност или лактация.
Да не се използва при животни с
нарушена чернодробна функция.
Да не се използва при
свръхчувствителност към активната
субстанция, или към някой от
ексципиентите.
Да не се използва при кучета, чието
наднормено тегло или затлъстяване се
дъ
                                
                                Read the complete document

Similar products

Active ingredient дирлотапид

дирлотапид

ATC code QA08AB91

QA08AB91

Marketed by Zoetis Belgium SA

Zoetis Belgium SA

INN (International Name) dirlotapide

dirlotapide

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 24-02-2015
Summary of Product characteristics Summary of Product characteristics Spanish 24-02-2015
Public Assessment Report Public Assessment Report Spanish 24-02-2015
Patient Information leaflet Patient Information leaflet Czech 24-02-2015
Summary of Product characteristics Summary of Product characteristics Czech 24-02-2015
Public Assessment Report Public Assessment Report Czech 24-02-2015
Patient Information leaflet Patient Information leaflet Danish 24-02-2015
Summary of Product characteristics Summary of Product characteristics Danish 24-02-2015
Public Assessment Report Public Assessment Report Danish 24-02-2015
Patient Information leaflet Patient Information leaflet German 24-02-2015
Summary of Product characteristics Summary of Product characteristics German 24-02-2015
Public Assessment Report Public Assessment Report German 24-02-2015
Patient Information leaflet Patient Information leaflet Estonian 24-02-2015
Summary of Product characteristics Summary of Product characteristics Estonian 24-02-2015
Public Assessment Report Public Assessment Report Estonian 24-02-2015
Patient Information leaflet Patient Information leaflet Greek 24-02-2015
Summary of Product characteristics Summary of Product characteristics Greek 24-02-2015
Public Assessment Report Public Assessment Report Greek 24-02-2015
Patient Information leaflet Patient Information leaflet English 24-02-2015
Summary of Product characteristics Summary of Product characteristics English 24-02-2015
Public Assessment Report Public Assessment Report English 24-02-2015
Patient Information leaflet Patient Information leaflet French 24-02-2015
Summary of Product characteristics Summary of Product characteristics French 24-02-2015
Public Assessment Report Public Assessment Report French 24-02-2015
Patient Information leaflet Patient Information leaflet Italian 24-02-2015
Summary of Product characteristics Summary of Product characteristics Italian 24-02-2015
Public Assessment Report Public Assessment Report Italian 24-02-2015
Patient Information leaflet Patient Information leaflet Latvian 24-02-2015
Summary of Product characteristics Summary of Product characteristics Latvian 24-02-2015
Public Assessment Report Public Assessment Report Latvian 24-02-2015
Patient Information leaflet Patient Information leaflet Lithuanian 24-02-2015
Summary of Product characteristics Summary of Product characteristics Lithuanian 24-02-2015
Public Assessment Report Public Assessment Report Lithuanian 24-02-2015
Patient Information leaflet Patient Information leaflet Hungarian 24-02-2015
Summary of Product characteristics Summary of Product characteristics Hungarian 24-02-2015
Public Assessment Report Public Assessment Report Hungarian 24-02-2015
Patient Information leaflet Patient Information leaflet Maltese 24-02-2015
Summary of Product characteristics Summary of Product characteristics Maltese 24-02-2015
Public Assessment Report Public Assessment Report Maltese 24-02-2015
Patient Information leaflet Patient Information leaflet Dutch 24-02-2015
Summary of Product characteristics Summary of Product characteristics Dutch 24-02-2015
Public Assessment Report Public Assessment Report Dutch 24-02-2015
Patient Information leaflet Patient Information leaflet Polish 24-02-2015
Summary of Product characteristics Summary of Product characteristics Polish 24-02-2015
Public Assessment Report Public Assessment Report Polish 24-02-2015
Patient Information leaflet Patient Information leaflet Portuguese 24-02-2015
Summary of Product characteristics Summary of Product characteristics Portuguese 24-02-2015
Public Assessment Report Public Assessment Report Portuguese 24-02-2015
Patient Information leaflet Patient Information leaflet Romanian 24-02-2015
Summary of Product characteristics Summary of Product characteristics Romanian 24-02-2015
Public Assessment Report Public Assessment Report Romanian 24-02-2015
Patient Information leaflet Patient Information leaflet Slovak 24-02-2015
Summary of Product characteristics Summary of Product characteristics Slovak 24-02-2015
Public Assessment Report Public Assessment Report Slovak 24-02-2015
Patient Information leaflet Patient Information leaflet Slovenian 24-02-2015
Summary of Product characteristics Summary of Product characteristics Slovenian 24-02-2015
Public Assessment Report Public Assessment Report Slovenian 24-02-2015
Patient Information leaflet Patient Information leaflet Finnish 24-02-2015
Summary of Product characteristics Summary of Product characteristics Finnish 24-02-2015
Public Assessment Report Public Assessment Report Finnish 24-02-2015
Patient Information leaflet Patient Information leaflet Swedish 24-02-2015
Summary of Product characteristics Summary of Product characteristics Swedish 24-02-2015
Public Assessment Report Public Assessment Report Swedish 24-02-2015
Patient Information leaflet Patient Information leaflet Norwegian 24-02-2015
Summary of Product characteristics Summary of Product characteristics Norwegian 24-02-2015
Patient Information leaflet Patient Information leaflet Icelandic 24-02-2015
Summary of Product characteristics Summary of Product characteristics Icelandic 24-02-2015

Search alerts related to this product

Alerts Slentrol дирлотапид dirlotapide

Slentrol дирлотапид dirlotapide

View documents history

Documents history Documents history

Slentrol